Zināšanu bāze

Vispirms paskaidrojam, tad pārdodam.

Faktiskas, ar avotiem pamatotas piezīmes par mūsu pārdotajiem savienojumiem un to, kā tie tiek pārbaudīti. Tikai pētniecības konteksts - bez devu, lietošanas vai veselības norādījumiem.

News · 7 minRetatrutide phase 3 in 2026: all four TRIUMPH readouts, the Lancet paper and the dysesthesia signalFour retatrutide phase 3 trials have now reported and TRIUMPH-2 is peer-reviewed in The Lancet. Weight loss, HbA1c, safety signals and the 2027 filing plan.Lasīt →News · 6 minWADA 2027 Prohibited List: what changes for peptidesWADA's 2027 List names peptides explicitly in S0, keeps BPC-157, TB-500, CJC-1295, ipamorelin and MOTS-c prohibited, and leaves GLP-1 agonists off. What changed.Lasīt →News · 6 minFDA peptide review 2026: BPC-157 off Category 2, advisory panel votes on compoundingIn 2026 the FDA took BPC-157 and 11 other peptides off Category 2 and its advisers backed six for compounding. What is confirmed and what it means in the EU.Lasīt →Comparison · 8 minTirzepatide vs Retatrutide: mechanism, trial results and key differencesTirzepatide (dual GIP/GLP-1) vs retatrutide (triple GIP/GLP-1/glucagon): mechanism, SURMOUNT vs TRIUMPH trial results, side effects and approval status in 2026.Lasīt →Comparison · 8 minBPC-157 vs TB-500: mechanism, research findings and key differencesBPC-157 vs TB-500 compared: origin, how each works, what rat and cell studies report, TB-500 vs thymosin beta-4, WADA and FDA status, plus a side-by-side table.Lasīt →Guide · 9 minGLP-1 peptides explained: GLP-1, GIP and glucagon agonists from exenatide to retatrutideWhat GLP-1, GIP and glucagon receptor agonists are, how they evolved from exenatide to retatrutide, what trials showed, and which are approved in 2026.Lasīt →Guide · 7 minHealing peptides guide: BPC-157, TB-500, GHK-Cu, KPV and the GLOW / KLOW blendsA research guide to healing peptides: what BPC-157, TB-500, GHK-Cu and KPV are studied for, how strong the evidence is, and how the GLOW and KLOW blends fit in.Lasīt →Comparison · 8 minGLOW vs KLOW: what KPV adds to the BPC-157, TB-500 and GHK-Cu blendGLOW vs KLOW: same BPC-157, TB-500 and GHK-Cu repair trio, but KLOW adds 10 mg KPV, an anti-inflammatory tripeptide. Components, research and table.Lasīt →Comparison · 8 minCJC-1295 with DAC vs without DAC: half-life, research data and key differencesCJC-1295 with DAC binds albumin and lasts about a week; no-DAC (Mod GRF 1-29) acts for minutes, in pulses. Human data, ipamorelin pairing and a table.Lasīt →Glossary · 10 minPeptide glossary: 40 terms from HPLC and COA to GLP-1 and Phase 3Plain-language definitions of 40 terms you meet when buying or analysing research peptides: HPLC, LC-MS, COA, TFA salt, lyophilization, GLP-1, DAC and more.Lasīt →Regulatory · 6 minThe 2025-2026 incretin approvals, and where research compounds sitThree GLP-1 drugs cleared the FDA in seven months. What was approved, and how investigational compounds like retatrutide differ.Lasīt →Compound · 7 minRetatrutide: a triple receptor agonist in Phase 3What retatrutide is at the molecular level, what its TRIUMPH trials reported, and why it is still investigational.Lasīt →Compound · 6 minMOTS-c: a mitochondria-derived signalling peptideA peptide written into the mitochondrial genome, why it is called an exercise mimetic, and what recent studies examined.Lasīt →Quality · 5 minWhat “≥99 % purity” actually meansA purity number is only meaningful with its method and its batch. Here is what the figure includes - and what it does not.Lasīt →Handling · 4 minLyophilised peptides and temperatureWhy freeze-dried powder is stable, how it is stored, and when stability is lost. Storage facts only - no reconstitution or usage instructions.Lasīt →Methods · 5 minHPLC and LC-MS: two different questionsOne method tells you how much is there; the other tells you whether it is the right molecule. Why a report uses both.Lasīt →